562 related articles for article (PubMed ID: 17612710)
1. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
3. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
4. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Fenaux P
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
7. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
8. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
10. Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Stresemann C; Bokelmann I; Mahlknecht U; Lyko F
Mol Cancer Ther; 2008 Sep; 7(9):2998-3005. PubMed ID: 18790780
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.
Szmigielska-Kapłon A; Robak T
Curr Cancer Drug Targets; 2011 Sep; 11(7):837-48. PubMed ID: 21762079
[TBL] [Abstract][Full Text] [Related]
12. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
13. Review: recent clinical trials in epigenetic therapy.
Oki Y; Issa JP
Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
[TBL] [Abstract][Full Text] [Related]
14. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
15. The role of decitabine in the treatment of myelodysplastic syndromes.
Atallah E; Kantarjian H; Garcia-Manero G
Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
[TBL] [Abstract][Full Text] [Related]
16. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
17. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
18. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK
Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
[TBL] [Abstract][Full Text] [Related]
19. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
20. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
